New Enterprise Associates
http://www.nea.com/Home/New Enterprise Associates is a venture capital firm based in Baltimore, MD. The firm has backed more than 160 companies that have gone public and invested in more than 230 companies that have been successfully merged or acquired. NEA focuses its investments in the information technology, healthcare, and energy technology industries. While NEA makes a majority of its investments in the United States, the firm invests around the world in China and India. The firm was founded in 1978.
View Older Stories View More Recent Stories
-
Black Diamond Therapeutics (BDTX) Announces Spinout of Launchpad Therapeutics, Inc., an Antibody-Focused Precision Oncology Company
-
Black Diamond Therapeutics Announces Spinout of Launchpad Therapeutics, Inc., an Antibody-Focused Precision Oncology Company
-
Lumos Pharma, Inc. (LUMO) Announces KOL Review of Interim Phase 2 Data Supports Potential for New Oral Therapeutic Paradigm for Moderate Idiopathic PGHD Patients
-
KOL Review of Lumos Pharma’s Interim Phase 2 Data Supports Potential for New Oral Therapeutic Paradigm for Moderate Idiopathic PGHD Patients
-
Celcuity Closes $100 Million Private Placement
-
KOL Review of Lumos Pharma’s Interim Phase 2 Data Supports Potential for New Oral Therapeutic Paradigm for Moderate Idiopathic PGHD Patients
-
IMAS Announces Dr Scott Gottlieb as Keynote Speaker for ACCESS 2023 in Miami Beach
-
Stride Health Appoints Peter V. Lee, Former Executive Director of Covered California, to Board of Directors
-
Timescale Announces Appointment of Virginia Liu as Chief Marketing Officer
-
Celcuity Announces First Patient Dosed in Phase 3 VIKTORIA-1 Clinical Trial of Gedatolisib for the Treatment of HR+/HER2- Advanced Breast Cancer
-
Lumos Pharma to Host KOL Webinar to Discuss Interim Phase 2 Data from OraGrowtH Trials in PGHD
-
Lumos Pharma to Host KOL Webinar to Discuss Interim Phase 2 Data from OraGrowtH Trials in PGHD
-
Escient Pharmaceuticals Announces $120 Million Series C Financing
-
Lumos Pharma to Participate in the Piper Sandler 34th Annual Healthcare Conference
-
Lumos Pharma to Participate in the Piper Sandler 34th Annual Healthcare Conference
-
Form SC 13D/A Oyster Point Pharma, Filed by: New Enterprise Associates 14, L.P.
-
Form 4 IonQ, Inc. For: Nov 16 Filed by: New Enterprise Associates 15, L.P.
-
Timescale advances best-in-class price performance for developers with launch of new object storage layer on Amazon S3
-
Braintrust Tutors Adds Notable Investors Scott Sandell and John Chambers
-
Braintrust Tutors Adds Notable Investors Scott Sandell and John Chambers
-
Affordability Education Gap Is No. 1 Barrier to Increasing Independent and Gig Worker Health Coverage Rate, Per New Stride Health Survey
-
New Wave Foods® Announces Partnership with Restauranteur, Influencer and Television Personality Chef Brian Duffy
-
ReCode Therapeutics Establishes Scientific Advisory Board
-
MBX Biosciences Closes $115 Million Series B Financing to Advance Development of Endocrine Disease Programs
-
Lumos Pharma Reports Third Quarter 2022 Financial Results and Clinical Development Updates
-
Lumos Pharma Reports Third Quarter 2022 Financial Results and Clinical Development Updates
-
Lumos Pharma (LUMO) Reports Encouraging Interim Results from Two Phase 2 Trials of Oral LUM-201
-
Lumos Pharma Announces Encouraging Interim Results from Two Phase 2 Trials Evaluating Oral LUM-201 for Moderate Pediatric Growth Hormone Deficiency
-
Lumos Pharma Announces Encouraging Interim Results from Two Phase 2 Trials Evaluating Oral LUM-201 for Moderate Pediatric Growth Hormone Deficiency
-
Rise and fall of crypto exchange FTX
-
Rise and fall of crypto exchange FTX
-
Allakos Provides Business Update and Reports Third Quarter 2022 Financial Results
-
Allakos Provides Business Update and Reports Third Quarter 2022 Financial Results
-
Glasswing Ventures Announces Key Additions to Team, Fulfilling its Building Partner Vision
-
Pionyr Immunotherapeutics’ MARCO-targeting Antibody Program, PY265, for Treatment of Solid Tumors Featured at SITC 2022
-
Form SC 13D/A PhaseBio Pharmaceuticals Filed by: NEW ENTERPRISE ASSOCIATES 13 LP
-
PMV Pharmaceuticals (PMVP) Appoints Carol Gallagher to its Board
-
PMV Pharmaceuticals Appoints Industry Veteran Dr. Carol Gallagher to Board of Directors
-
Courtyard Raises $7M in Seed Funding To Redefine Physical Collectibles Ownership Through NFTs
-
TMRW Sports Adds All-Star Investors
-
Form SC 13D/A Akouos, Inc. Filed by: New Enterprise Associates 16, L.P.
-
Form 4 PhaseBio Pharmaceuticals For: Oct 25 Filed by: NEW ENTERPRISE ASSOCIATES 13 LP
-
Timescale Announces Appointment of Jason Montgomery as VP, Sales.
-
Wispr Raises Another $10M to Build a More Natural Way to Interact with Technology
-
Form 4 AVEO PHARMACEUTICALS, For: Oct 19 Filed by: New Enterprise Associates 15, L.P.
-
Form SC 13D/A Bright Health Group Inc. Filed by: New Enterprise Associates 15, L.P.
-
Topia Launches Remote Work Solution, Automating Immigration and Tax Compliance for HR Teams
-
Inversago Pharma Announces Appointment of Ed Mathers, BSc and Nanna Lüneborg, PhD, MBA to its Board of Directors
-
Swift Navigation Raises $100 Million Series D Financing Round to Bring Safe and Precise Navigation to Every Vehicle on the Planet
-
Swift Navigation Raises $100 Million Series D Financing Round to Bring Safe and Precise Navigation to Every Vehicle on the Planet

